Aristea Therapeutics, Inc.
http://aristeatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aristea Therapeutics, Inc.
China Pharma Embraces AI Tools Amid Globalization Challenges
The Chinese biopharma industry is eager to use the latest artificial intelligence technology to boost efficiency and lighten workloads, as companies deal with drastic change and look to improve their understanding of foreign markets. Meanwhile, senior European leaders called for a level playing field during a recent visit to China.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.
Insilico's Co-CEO Talks AI, ChatGPT And The Future Of Drug Discovery
After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field.
AI, ChatGPT And The Future Of Drug Discovery: China Biotech CEO Podcast With Insilico's Co-CEO
After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice